Steris (STE) Net Income towards Common Stockholders (2018 - 2026)
Steris (STE) posted Net Income towards Common Stockholders of $201.0 million for Q2 2026, down 8.76% on a QoQ basis from $220.3 million in Q1 2026, and up 12.92% year-over-year from $178.0 million in Q2 2025.
Analysis
Steris (STE) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Steris has reported Net Income towards Common Stockholders for 9 years, with the latest figure at $201.0 million in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 12.92% year-over-year to $201.0 million in Q2 2026; TTM through Jun 2026 was $808.1 million, a 24.63% increase from a year earlier, with the FY2026 full-year figure at $785.1 million, up 27.45% from the prior year.
- Net Income towards Common Stockholders was $201.0 million for Q2 2026 at Steris, down from $220.3 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $220.3 million in Q1 2026, with the low at -$315.2 million in Q3 2022.
- Average Net Income towards Common Stockholders over 5 years is $121.2 million, with a median of $145.8 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders plunged 552.76% in 2022, then surged 14670.86% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at $123.3 million in 2022, then grew by 14.29% to $140.9 million in 2023, then gained by 22.88% to $173.2 million in 2024, then gained by 12.18% to $194.3 million in 2025, then rose by 3.45% to $201.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $201.0 million (Q2 2026), $220.3 million (Q1 2026), and $194.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.54 Bn | 177.93 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 124.70 Bn | 119.48 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.91 Bn | 109.09 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 105.72 Bn | 102.25 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 49.52 Bn | 45.27 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.89 Bn | 32.43 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.10 Bn | 30.15 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.06 Bn | 20.58 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Zimmer Biomet Holdings | 18.26 Bn | 17.85 Bn | 1.54 Bn | 199.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 201.00 Mn |
| Mar 31, 2026 | 220.30 Mn |
| Dec 31, 2025 | 194.30 Mn |
| Sep 30, 2025 | 192.50 Mn |
| Jun 30, 2025 | 178.00 Mn |
| Mar 31, 2025 | 146.00 Mn |
| Dec 31, 2024 | 173.20 Mn |
| Sep 30, 2024 | 151.20 Mn |
| Jun 30, 2024 | 145.50 Mn |
| Mar 31, 2024 | -1.00 Mn |
| Dec 31, 2023 | 140.95 Mn |
| Sep 30, 2023 | 116.35 Mn |
| Jun 30, 2023 | 123.79 Mn |
| Mar 31, 2023 | 186.96 Mn |
| Dec 31, 2022 | 123.33 Mn |
| Sep 30, 2022 | -315.23 Mn |
| Jun 30, 2022 | 110.76 Mn |
| Mar 31, 2022 | 93.64 Mn |
| Dec 31, 2021 | 143.09 Mn |
| Sep 30, 2021 | 69.63 Mn |